Global Cholera Vaccines Market, By Product Type (Vaxchora, Dukoral, ShanChol, Euvichol-Plus/Euvichol, Others), By Vaccine Type (Killed Whole-cell and Recombinant Cholera Toxin B Vaccine, Killed Whole-cell Only Vaccines, Live Attenuated Oral Cholera, Vacci

Global Cholera Vaccines Market, By Product Type (Vaxchora, Dukoral, ShanChol, Euvichol-Plus/Euvichol, Others), By Vaccine Type (Killed Whole-cell and Recombinant Cholera Toxin B Vaccine, Killed Whole-cell Only Vaccines, Live Attenuated Oral Cholera, Vaccine), By Patient Type (Pediatric, Adults), By Distribution Channel (Public, Private), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

The global cholera vaccines market was valued US$ 82.5 Mn in 2023 and is expected to reach US$ 204.6 Mn by 2031, growing at a compound annual growth rate (CAGR) of 12% from 2024 to 2031.

Figure 1. Global Cholera Vaccines Market Share (%), By Region, 2023

Cholera is a bacterial disease that usually spreads through contaminated water. It causes severe diarrhea and dehydration and can be fatal within hours if left untreated. The disease is most prevalent in areas with inadequate water treatment, poor sanitation, and inadequate hygiene, such as Africa, Southeast Asia, and Haiti. The World Health Organization (WHO) and the UN Children’s Fund (UNICEF) have warned that cholera is making a devastating comeback, particularly targeting vulnerable communities. The risk of a cholera epidemic is highest when poverty, war, or natural disasters force people to live in crowded conditions without adequate sanitation. Cholera is a disease of poverty, affecting people with inadequate access to safe water and basic sanitation. The infection is not likely to spread directly from one person to another; therefore, casual contact with an infected person is not a significant risk factor for becoming ill. In terms of prevention, a multifaceted approach is key to controlling cholera and reducing deaths. This includes ensuring access to safe water, adequate sanitation, and hygiene, as well as vaccination in high-risk areas.

Market Dynamics:

Key drivers favoring the growth of global cholera vaccines market include the rising burden of cholera disease globally, growing focus on preventing cholera outbreaks, and the development of novel oral vaccines with a longer duration of protection. However, factors such as insufficient access to vaccines in low-income regions, and a lack of awareness about immunization in certain communities continue to restrain the market potential to a certain extent. On the optimistic side, increasing investments in the research of vaccines providing cross-protection against multiple serotypes open up new avenues. Partnerships between makers and international organizations for improving availability in endemic areas also present attractive opportunities over the next few years.

Key features of the study:

• This report provides in-depth analysis of the global cholera vaccines market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2024–2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global cholera vaccines market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies - Key companies covered as a part of this study include Sanofi, Biovac.co.za., EMERGENT, Celldex Therapeutics, Valneva SE, Hilleman Laboratories, Shanghai United Cell Biotechnology Co., Ltd (Hillhouse Capital), PaxVax, Inc., Astellas Pharma Inc., and EUBIOLOGICS CO., LTD.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global cholera vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cholera vaccines market

Detailed Segmentation:

• Global Cholera Vaccines Market, By Product Type
• Vaxchora
• Dukoral
• ShanChol
• Euvichol-Plus/Euvichol
• Others (Late Phase Vaccines, etc.)
• Global Cholera Vaccines Market, By Vaccine Type
• Killed Whole-cell and Recombinant Cholera Toxin B Vaccine
• Killed Whole-cell Only Vaccines
• Live Attenuated Oral Cholera Vaccine
• Global Cholera Vaccines Market, By Patient Type
• Pediatric
• Adults
• Global Cholera Vaccines Market, By Distribution Channel
• Public
• Private
• Global Cholera Vaccines Market, By Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa
• Top Companies in the Global Cholera Vaccines Market:
• Sanofi
• Biovac.co.za.
• EMERGENT
• Celldex Therapeutics
• Valneva SE
• Hilleman Laboratories
• Shanghai United Cell Biotechnology Co., Ltd (Hillhouse Capital)
• PaxVax, Inc.
• Astellas Pharma Inc.
• EUBIOLOGICS CO., LTD.